cognitive decline and alzheimer’s disease: the influence of...
Post on 28-May-2020
6 Views
Preview:
TRANSCRIPT
4/3/2018
1
Cognitive Decline and Alzheimer’s Disease:
The Influence of Nutrition
Cynthia Lieu, Pharm.D., BCNSP
Naomi Quint, Melody Armiteh, Kelly Tran
University of Southern California, School of Pharmacy
April 13, 2018
Objectives
• Describe nutrients and foods that negatively affect cognitive function or increase the risk for Alzheimer’s Disease (AD)
• Describe nutrients and foods that positively affect cognitive function or reduce the risk for AD
• Design a nutritional plan to reduce the risk of cognitive decline and AD
Dementia: decline in mental ability severe enough to interfere with daily life
• Alzheimer’s disease (AD): most common type
– Brain changes may begin 20 years before symptoms begin
• Other types of dementia:
– Vascular dementia
– Frontal-temporal dementia
– Parkinson's dementia
– Lewy-Body dementia
4/3/2018
2
• Subjective cognitive decline (SCD)
– Subjectively perceived subtle cognitive deficits
– Neuropsychological testing: normal performance
• Mild cognitive impairment (MCI)
– Neuropsychological test results: mildly reduced
• Neuropsychological tests
– Memory, visuoconstruction, attention/processing speed, executive functioning
• Pathophysiological processes take place years before AD manifestation
Eliassen, et al. Brain Behav. 2017;7(9): e00776.
Subjective Cognitive Decline (SCD)
Mild Cognitive Impairment
(MCI)Dementia
Warning signs of Alzheimer’s• Memory loss that disrupts daily life
• Challenges in planning or solving problems
• Difficulty completing familiar tasks at home, at work or at leisure
• Confusion with time or place
• Trouble understanding visual images & spatial relationships
• New problems with words in speaking or writing
• Misplacing things & losing the ability to retrace steps
• Decreased or poor judgment
• Withdrawal from work or social activities
• Changes in mood & personality
https://www.alz.org/alzheimers_disease_10_signs_of_alzheimers.asp. Accessed March 31, 2018.
Tests used for AD & cognitive impairment• Mini-Mental State Examination (MMSE)
– Overall measure of cognitive impairment
– 30 point questionnaire
– 20-24 = mild dementia; 13-20 = moderate dementia; <12 = severe dementia.
• Alzheimer Disease Assessment Scale (ADAS-cog)1
– Evaluates memory, attention, language, orientation, and praxis
– 70-point scale
– Higher scores indicate greater impairment1Aisen, et al. JAMA. 2008;300(15):1774-1783.
4/3/2018
3
• Alzheimer’s Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory1
– Assesses functional ability to perform activities of daily living in patients with AD
– Scores range from 0 to 78
– Lower scores indicate worse function
• Neuropsychiatric Inventory (NPI)2
– Assessment of severity and frequency of psychological and behavioral disturbances in patients with dementia
• Delusions, hallucinations, dysphoria, anxiety, agitation, euphoria, disinhibition, irritability, apathy, and aberrant motor activity
– Provides scores for 10 subscales1Dysken, et al. JAMA. 2014;311(1):33-44.
2Cummings, et
al. Neurology. 1994;44(12):2308-14.
Alzheimer's Disease Facts & Figures, U.S.• 2018:
– 5.7 million Americans• 2025, estimated: 7.1 million• 2050, projected: nearly 14 million
– Projected health & long-term care, individual with AD: $424,000
– Alzheimer’s & other dementias, cost of care: $277 billion• 2050, projected: $1.1 trillion
• Leading cause of disability & poor health• 6th leading cause of death in US
– 5th leading cause of death, 65 & older• 1 in 3 seniors dies with Alzheimer’s or another dementia
https://www.alz.org/documents_custom/2018-Facts-and-Figures-Press-Release.pdf. Accessed March 31, 2018.
Risk Factors • Apolipoprotein E (ApoE) ɛ4 allele1
• Oxidative stress2
– Transition metal accumulation
– Mitochondrial dysfunction
– Amyloid-β
• Diabetes3
• Elevated blood homocysteine (Hcy) levels4
1Liu, et al.Nat Rev Neurol 2013; 9(2): 106-118. 2Smith, et al. Biochim Biophys Acta. 2000;1502:139-144. 3Arvanitakis, et al. Arch Neurol. 2004;61(5):661-6. 4Smith, et al. J Alzheimers Dis 2018; 62(2): 561-570.
4/3/2018
4
Risk Factors – Nutrition-Related
• Significantly low protein intake1
• Very low sodium diets2
• Calcium supplementation3
• Aluminum-containing additives in food/water4
• Dietary patterns associated with mild cognitive impairment5
– Lower consumption of fish & more red meat– Low plasma concentration of HDL cholesterol– Low total antioxidant capacity & alpha-tocopherol
1Koh, et al. Nurtients 2015;7(4):2415-2439. 2Rush, et al. J Nutri Health Aging 2017;21(3):276-283. 3Kern, et al. Neurology 2016;87:1674–1680. 4Solfrizzi, et al. J Alzheimers Dis 2006;10(2-3):303-30. 5Yuan, et al. Nutrition. 2016;32(2):193-8.
Risk Factors – Nutrition-Related
• Increased cerebral amyloid plaque burden1
– High glycemic load diet
– High carbohydrate intake
– High sugar intake
• Reduced cognitive performance
1Taylor, et al. Am J Clin Nutr. 2017;106(6):1463-1470.
Nutritional Interventions:Dietary Supplements• Vitamin B12 & B6
• Folic acid
• Antioxidants
• Vitamin D
• Omega 3
• Herbs
4/3/2018
5
Elevated Homocysteine
• Risk factor for cognitive impairment, dementia1
– Vascular mechanisms
– Regional brain atrophy
– Neurofibrillary tangle & amyloid plaque formation
– Neuronal death
– Epigenetic mechanisms
• Studies: variety of cut-offs
• 2018 international consensus: suggested threshold, 10-11 umol/L1
1Smith, et al. J Alzheimers Dis 2018; 62(2): 561-570.
Folic Acid (FA, Vitamin B9)
Dose/Duration Participants Results
Folic acid 15 mg/d x 60 days1
N = 30Age = 65+Cognitive declineFolate levels < 3 ng/ml (low)
FA vs placebo: Attention efficiency score significantly improved
FA 800 mcg/d x 3 years2
N = 818Age = 50-70From NetherlandsHcy levels > 13 μmol/L (elevated)
FA vs placebo: Plasma Hcy decreased by 26%Global cognitive function improved (based on 5 cognitive tests)
1Fioravanti, et al. Arch Gerontol Geriatr 1998;26(1):1-13. 2Durga, et al. Lancet 2007;369(9557):208-216.
Combination Supplements
Dose/Duration Participants Results
Vit B12 1 mg/d & FA 5 mg/dx 2 months1
N = 28: mean age = 74Mild to moderate dementia (VaD, FTD, AD, mixed dementia, or other dementia)
High Hcy at baseline: Improved MMSE & memory &attention scoresNormal baseline Hcy: No changes
Vit B12 1000 mcg/d alone or with FA 400 mcg/d x 24 weeks2
N = 195: age = 70+No to moderate cognitive impairmentFrom NetherlandsMild vit B12 deficiencyMean plasma Hcy 14.5-15.8 (high)
Supplement (vit B12 or vit B12 + FA) vs placebo: vit B12 levels corrected & Hcy levels reduced by 16% (vit B12 group) & 37% (vit B12 + FA)No improvement in cognitive function vs placeboImproved memory in placebo group vs vit B12 group
1Nilsson, et al. Int J Geriatr Psychiatry. 2001;16(6):609-14.
2Eussen, et al. Am J Clin Nutr. 2006;84(2):361-70.
4/3/2018
6
Dose/Duration Participants Results
Vit B12 1 mg/d, FA 5 mg/d & vit B6 25 mg/d, x 18 months1
N = 344Age = 50+ yrsProbable ADNormal vit B12 & folate levelsMean plasma Hcy= 9.2 (SD = 3.2)
Supplement vs placebo: Hcy levels decreased by -2.4 vs -0.9No improvement in cognitive function
Vit B12 0.5 mg/d, FA 0.8 mg/d & vit B6 20 mg/dvs placebo, x 2 yrs
N = 223Age = 70+ yrsMCI
Supplement vs placebo:Hcy decreased (increased with placebo)High Hcy: Decline in rate of brain atrophySlowed cognitive decline (significant decline with placebo)
1Aisen, et al. JAMA. 2008;300(15):1774-1783;
2de Jager, et al.
Int J Geriatr Psychiatry 2012; 27: 592-600
Antioxidants
Oxidative Stress in AD
• Cellular respiration generates free radical intermediates (ROS formation)
• Sequestration mechanisms unable to capture all ROS
• Cellular respiration generates free radical intermediates (ROS formation)
• Sequestration mechanisms unable to capture all ROS
Reactive Oxygen Species
• Neurons vulnerable to oxidative damage
• Lipid peroxidation• Reactive carbonyls• Nitration• Nucleic acid
oxidation
• Neurons vulnerable to oxidative damage
• Lipid peroxidation• Reactive carbonyls• Nitration• Nucleic acid
oxidation
Oxidative Damage
• Formation of Aβ in neurons
• Compensatory mechanism: partial protection against oxidative damage in neurons
• Formation of Aβ in neurons
• Compensatory mechanism: partial protection against oxidative damage in neurons
Amyloid-β
Bonda, et al. Neuropharmacology. 2010;59(4-5):290-4.
AntioxidantsProtection against neurotoxicity
due to oxidative stress
4/3/2018
7
Dose/Duration Participants Results
Vit E 2000 IU/day in 2 divided doses, vs memantine 20 mg/day, vs vit E + memantine, vs placebo,x 6 months-4 years1
N = 613Mean age 78.897% men (veterans)Possible or probably ADMMSE = 21
Delayed decline in ADCS-ADL & reduced caregiver time in vit E groupEffect not seen in other treatment groups No statistically significant differences in MMSE, ADAS-cog, or NPI
Vitamin E
1Dysken, et al. JAMA. 2014;311(1):33-44
Dose/Duration Participants Results
Acetyl-L-carnitine (ALCAR) 1 g TID x 1 year1
N = 229Age = 45-65Probable AD (young-onset)
ALCAR vs placebo: No significant difference in the rate of decline in ADAS-cog scoreLess decline in MMSE
Alpha-lipoic acid (ALA) 600 mg/dx 16 months2
N = 126AD with T2DM (Group A) & without T2DM (Group B)
Group A vs Group B:Significant improvements in MMSE, ADAS-cog, CIBIC scores
N-Acetylcysteine (NAC) 50 mg/kg/day in 3 divided doses x 6 months3
N= 43Probable ADMMSE scores between 12 & 26
NAC vs placebo: Trend to perform better on MMSE & the Wechsler Memory Scale Performed significantly better on letter fluency task
Antioxidants
1Thal, et al. Neurology 2000;55:805–10. 2Fava, et al. J Neurodegener Dis. 2013;2013:454253. 3Adair, et al. Neurology. 2001;57(8):1515-7.
Dose/Duration Participants Results
ALCAR 500 mg, NAC 600 mg, S-adenosylmethionine (SAM) 400 mg (200 mg active ion), vit E 30 IU, FA 400 mcg & vitB12 6 mcg x 3-6 months2
N= 106Probable AD &/or senile dementia of the Alzheimer type
Supplement vs placebo: Cognitive performance (Clox-1 & DRS) improvedNo statistical change in BPSD
Combination Supplements
2Remington, et al. J Alzheimers Dis. 2015;45(2):395-405.
4/3/2018
8
Vitamin D deficiencyVitamin D deficiency
• Serum 25-hydroxyvitamin D concentrations ≤ 20 ng/mL (50 nmol/L)
• 41.6% deficient in the US general population• 82.1% blacks, 69.2% Hispanics• No college education, obese, poor health status, HTN,
no daily milk consumption, high cholesterol
Forrest, et al. Nutr Res.2011;31(1):48-54.
Vitamin D
Amyloid-B
TAU
Inflammatory stressOxidative stress
Vascular stress
Neuronal death Decline in Memory & learning
• Role of vitamin D mediated by VDRs• Clearance of AB peptide• Anti-inflammatory action• Antioxidant action• Primary prevention and reduction of ischemic zone size
Annweiler, et al.Front.Pharmacol.2014;5:6
Vitamin D
1Zhao, et al. Nutrition 2013;29(6):828-32.
2Afzal, et al. Alzheimer's
& Dementia 2014;10:296–302.3Olsson, et al. Am J Clin Nutr.
2017;105(4):936-943.
Dose/Duration Participants ResultsVit D1 6 studies on AD patients
319 patients, 573 controlsAge 65+
AD patients: Either vit D deficient or had insufficient plasma vit D levels(Insufficient <20 ng/ml; Deficient<10 ng/ml)
Vit D2 N = 10,186White Danish individuals30 years follow up
Lower plasma vit D levels:Increase risk of AD & vascular dementia
Vit D3 N = 1182 Swedish menMean age 7118 years follow up(<20ng/mL, 20-30ng/mL, >30ng/mL)
No association between baseline vit D status & long term risk of dementia or cognitive decline
4/3/2018
9
Vitamin D Combination
Dose/Duration Participants Results
Memantine 20 mg, vs vit D 400-1000 IU, vs Memantine + vit D, x 6 mo.
43 white patientsNew diagnosis of ADNo anti-dementia drug or vit D supplementation before
Memantine + vit D group:Increased MMSE score by 4 pointsNo test score changes for the other two groups
Annweiler, et al. Cogn Behav Neurol 2012;25(3):121-127.
Omega 3 PUFAs: DHA & EPA
• Brain requires DHA1
– Production and clearance of ß-amyloid– Maintenance of neuronal membranes – Modulation of inflammation – Improvement of vascular health
• Dementia2
– Decreased DHA– Decreased EPA– Decreased total n-3 PUFAs
• Predementia2
– Decreased EPA
1Yassine, et al. JAMA neurology. 2017;74(3):339-347. 2Lin, et al. J Clin Psychiatry 2012; 73(9): 1245-1254.
Dose/Duration Participants Results
4 capsules 1.6 g EPA & 0.8 g DHA/day1
Healthy older adults Age = 62-80Subjective memory impairment (not meeting criteria for MCI or AD)
Red blood cell omega 3 content, working memory performance & blood oxygen level dependent (BOLD) signal increased
High dose DHA/EPA ranging from 150-2200 mg/d2
Mice: APOE4 carriers & non-carrier with or without AD
Incidence of AD was reduced significantly in APOE4 carriers
1.7 g of DHA + 0.6 g of EPA, vs. placebo, x 6 mo3
N = 204Mean age = 74ADMMST score of 15
No delay in rate of cognitivedecline in patient with mild-moderate ADPositive effect on patient with very mild AD
Omega 3
1Boespflug, et al.J Nutr Health Aging 2016; 20(2):161-9 2Yassine, et al. JAMA Neurology. 2017;74(3):339-3473Freund-Levi, et al. Neurol 2006 ;63:1402–8.
4/3/2018
10
N-3 PUFAs on dementia• Observational studies1
– Beneficial in 17 studies
• Higher level of ALA: decreased risk
• Higher level of DHA: decreased risk
• Fatty fish > 2/wk vs < 1/month: decreased risk
– No benefit in 3 studies
• Intervention studies1
– Beneficial in 8 studies
– No benefit in 5 studies
• APOE e4 carriers2
– More vulnerable to dietary n-3 deficits
– Supplementation with DHA as early as possible might help to prevent onset of AD
1Yanai, J Clin Med Res 2017; 9(1): 1-9; 2Nock, et al. Biochem Biophys Acta 2017; 1862(10 Pt A): 1068-1078.
Dementia can be improved or prevented by n-3 PUFA• Mild memory &/or cognitive impairment
– Subjective memory impairment
– Mild cognitive impairment
– Cognitive impairment no dementia
– Mild Alzheimer’s disease
• Higher intake of fish
• Additional daily n-3 PUFA intake > 2 g
• Additional daily DHA intake > 900 mg
• Duration of treatment > 6 mos
1Yanai, J Clin Med Res 2017; 9(1): 1-9.
Herbs
4/3/2018
11
Curcumin
• Compound in turmeric– Herb in the ginger family– Curcuma longa L.
• Spice in curry powder• Anti-inflammatory1
• Powerful antioxidant2
• Inhibits amyloid β formation2
1Srimal, et al. J Pharm Pharmacol. 1973;25:447-452. 2Mirmosayyeb, et al. Int J Prev Med. 2017;8:5.
CurcuminDose/Duration Participants ResultsCurcumin 80 mg single dose1
N = 60Healthy adultsAge 60-85
Acute curcumin vs placebo: Significantly improved sustained attention & working memory tasks 1 hour post dose
Curcumin 80 mg/d x 4 weeks1
Chronic curcumin vs placebo: Significantly improved working memory & mood
Curcumin 1500 mg capsules/d x 12 months2
N = 160Age 40-90No cognitive impairments
Curcumin vs placebo: Improved cognitive performance at 6 monthsNo differences between groups at 12 months
Theracurmin: curcumin 90 mg twice/d x 18 months3
N = 40Age = 51-84Non-demented
Curcumin vs placebo: Improved memory & attention Benefit associated with decreases in amyloid & tau accumulation
1Cox, et al. J Psychopharmacol. 2015;29(5):642-51. 2Rainey-Smith, et al. Br J Nutr. 2016;115(12):2106-13. 3Small, et al. Am J GeriatrPsychiatry. 2018;26(3):266-277
Sage
• Herbal supplement
• Antioxidant and anti-inflammatory
• Inhibits acetylcholinesterase (AChE)1,2
• CNS depressant
• Salvia officinalis
• S. lavandulaefolia
1Perry, et al. Pharmacol Biochem Behav 2003;75(3):651-9. 2Kennedy, et al. J Psychopharmacol 2011;25(8):1088-100.
4/3/2018
12
Sage ExtractDose/Duration Participants ResultsS. lavandulaefoliaessential oil50 mcg capsules QD x 1 week, then BID x 1 week, then TID x 4 weeks1
N = 11Age = 76-95Mild to moderate probable ADMMSE = 10-26
After 6 weeks of treatment: 14.4% decrease in AChE activity Improvements in Neuropsychiatric Inventory (NPI) measurementsMMSE scores stayed the same
S. lavandulaefoliaessential oil50 uL single dose2
N = 36Mean age = 23Healthy participants
S. lavandulaefolia vs placebo:Improved cognitive performance & moodImproved attention & memory performance 1-h post doseReduced mental fatigue & increased alertness more prominent 4-h post-dose
1Perry, et al. Pharmacol Biochem Behav 2003;75(3):651-9. 2Kennedy, et al. J Psychopharmacol 2011;25(8):1088-100.
Sage ExtractDose/Duration Participants Results
S. officinalisextract60 drops(~4 mL)/day x 4 months
N = 42Age = 65-80Mild to moderate ADScore > 12 on the ADAS-cog
S. officinalis vs placebo:Improved cognitive functions (ADAS-cog & CDR-SB scores)May reduce agitation
Akhondzadeh, et al. J Clin Pharm Ther. 2003;28(1):53-9.
Foods/Diet Plans
4/3/2018
13
Specific Foods/Fluids
Nutrients Food Sources
DHA, vitamin D Fatty fish
Monounsaturated fat Olive oil
Tocopherols (vitamin E) Leafy green vegetables
Flavonoids Berries
Polyphenols Red wine, green tea
Studies on Specific FoodsFoods Participants Results Fish1 N = 2233
Age = 65+ yrsLean fried fish: no effectFatty fish:APOE e4: no protective effectAPOE e4 negative: reduced risk of dementia & AD
Fish2 N = 5395Age = 55+ yrs
No association between fish intake & dementia risk
Olive oil3
N = 6947Age = 65+ yrs
High or moderate consumption of olive oil: Lower odds of cognitive deficit in visual memory & verbal fluency
1Huang TL, et al. Neurology 2005;65(9):1409-14.
2Devore EE, et al.
Am J Clin Nutr 2009;90(1):170-176.3Berr C, et al. Dement Geriatr
Cogn Disord 2009;28(4):357-364.
Foods Participants ResultsLeafy green vegetables1
N = 3,718Age = 65-102 yrsChicago60% Black, 62% FFood frequencyquestionnaireFollow-up: 3 & 6 yrs
Greater consumption of leafy green vegetables:Slower rate of cognitive decline> 2 vegetable servings/day = cognition 5 yrs younger Fruit consumption:No cognition benefit
Leafy green vegetables2
N = 960Age = 58-99 yrsFood frequency questionnaire & cognitive assessmentsMean 4.7 yrs (2-10)
Green leafy vegetable consumption (highest quintile: mean 1.3 servings/d; higher intakes of folate, phylloquinone& lutein):Slower cognitive declineEquivalent to 11 yrs younger vs rarely or never consumed green leafy vegetables
1Morris MC, et al. Neurology 2006;67(8):1370-1376.
2Morris MC, et al.
Neurology 2018; 90:e1-9.
4/3/2018
14
Foods Participants ResultsBerries1 N = 16,010 women
Age = 70+ yrsNurses’ Health StudyFood frequency questionnaire
Higher total flavonoidintake: Slower rates of cognitive declineBlueberries & strawberries (2+ servings/wk):Delayed cognitive aging by up to 2.5 yrs
Berries2 N = 9Age = 76.2 +/- 5.2 yrsEarly memory changesWild blueberry juice daily vs grape juice vs placebo, x 12 wks
Blueberry juice: Improved paired associate learning, word list recall
1Devore EE, et al. Ann Neurol 2012;72(1):135-43.
2Krikorian R, et
al. J Argic Food Chem 2010;58(7):3996-4000.
Foods Participants ResultsWine1 N = 980
Age = 65 yrsUp to 3 servings of wine daily: lower risk of AD
Green tea2
N = 1003Age = 70+ yrs
Green tea (> 3 cups/week):Lower prevalence of cognitive impairment
Tea3 N = 490Age = 60+ yrs
Green tea every day vs none:Cognitive decline (dementia or MCI): OR 0.32 (P=0.001)Dementia: OR 0.26 (P=0.06)
Black tea or coffee: no association for dementia or cognitive decline
1Luchsinger JA, et al. J Am Geriatr Soc 2004;52(4):540-6.
2Kuriyama
S, et al. Am J Clin Nutr 2006;83(2):355:61. 3Noguchi-Shinohara M, et
al. PLoS One 2014;9(5): e96013.
Foods Participants Results
Coffee1 N = 1409Age: 65-79 yrsAvg follow-up21 yrs
Coffee consumption at midlife vs no/little coffee: Lower risk of dementia & ADlater in lifeLowest risk (65% decrease): 3-5 cups/day
Coffee2 N = 676 men10-yr prospective cohort studyFinland, Italy, Netherlands
Coffee consumption vs non-consumers:Smaller cognitive declineInverse & J-shaped associationLeast cognitive decline: 3 cups of coffee/day
1Eskelinen MH, et al. J Alzheimers Dis 2009;16(1):85-91.
2Van Gelder
BM, et al. Eur J Clin Nutr 2007;61(2):226-32.
4/3/2018
15
DASH (Dietary Approaches to Stop Hypertension)
• Emphasis on:– Vegetables– Fruits– Whole grains– Low-fat or fat-free
dairy products– Lean meat, poultry, &
fish– Nuts, seeds, legumes
• Increased amounts: – Potassium– Calcium– Magnesium– Fiber
• Limit:– Saturated fat– Sugar-sweetened
beverages & sweets– Sodium
DASH Diet Participants Study Design Results
N = 16,144Age = 70+ yrsWomen1
Prospective cohort studyNurses’ Health Study
Long-term adherence: Better average cognitive function
N = 124Middle ageElevated BPSedentary & overweight or obese (BMI 25-40)2
Randomized control trialDASH alonevs DASH + weight management vs usual diet control group
DASH + weight managementand DASH alone: Greater neurocognitive improvements
1 Berendsen AAM, et al. J Am Med Dir Assoc 2017;18(5):427:432; 2Smith
PJ, et al. Curr Alzheimer Res 2012;8(5):510-519.
Mediterranean Diet
• High intake of:
– Extra virgin olive oil
– Vegetables, including leafy green vegetables
– Fruits
– Cereals
– Nuts & pulses/legumes
• Moderate intake of:
– Fish & poultry
– Dairy products
– Red wine
• Low intake of:
– Red meat
– Eggs
– Sweets
Davis, et al. Nutrients 2015; 7(11): 9139-9153.
4/3/2018
16
Mediterranean Diet Participants Study Design Results
N = 22581
No dementiaProspective study, NYFood frequency questionnaireEvaluated Q 1.5 yrsAdherence: 0-9 pts
262 cases of AD4 yr (0.2-13.9) follow-upFor AD vs lowest tertile:Highest tertile: HR 0.60 Middle tertile: HR 0.85
N = 5222
Age 55-80 yrs(74.6 +/- 5.7)High vascular risk
Randomized control trial, SpainMedDiet+EVOOvs MedDiet+Nutsvs low-fat diet (control)Mean follow-up: 6.5 yrs
MedDiet enhanced with EVOO or nuts: Better cognitive performanceMCI (60): 18 vs 19 vs 23Dementia (35): 12 vs 6 vs 17
1Scarmeas N, et al. Ann Neurol 2006;59(6):912-21.
2Martinez-Lapiscina EH, et al. J Neurol Neurosurg Psychiatry
2013;84(12):1318-25.
Dietary Plans
DASH DASH MedDietMedDiet MIND MIND
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND)
Whole grains 3/d
Green leafy vegetables 1/d
Other vegetables 1/d
Berries 2/wk
Fish 1/wk
Poultry 2/wk
Beans >3/wk
Nuts 5/wk
Alcohol/wine 1/d
Olive oil = primary oil
Fast/fried food <1/wk
Butter, margarine <1T/d
Cheese <1/wk
Red meats and products <4/wk
Pastries, sweets <5/wk
Morris MC, et al. Alzheimers Dement 2015;11(9):1007-1014.
4/3/2018
17
Rush Memory and Aging Project
• Prospective study, 2004-2013
• N = 923, 58-98 years old
• Evaluated 3 dietary patterns to incidence of AD
• Food frequency questionnaire
– Usual frequency of intake over previous 12 mos
– 144 items
• Mean of 4.5 years follow-up
– 151 AD cases developed
Morris MC, et al. Alzheimers Dement 2015;11(9):1007-1014.
DASH (max total score 10)
Components Max score Components Max score
Total grains ≥ 7/d 1 Total fat ≤ 27% of kcal
1
Vegetables ≥ 4/d 1 Saturated fat ≤ 6% of kcal
1
Fruits ≥ 4/d 1 Sweets ≤ 5/wk 1
Dairy ≥ 2/d 1 Sodium ≤ 2400 mg/d 1
Meat, poultry & fish ≤ 2/d
1
Nuts, seeds & legumes ≥ 4/wk
1
Morris MC, et al. Alzheimers Dement 2015;11(9):1007-1014.
MedDiet (max total score 55)
Components Max score Components Max score
Nonrefined Grains > 4/d
5 Legumes, nuts & beans > 6/wk
5
Vegetables > 4/d 5
Potatoes > 2/d 5 Olive oil ≥ 1/d 5
Fruits > 3/d 5
Full-fat Dairy ≤ 10/wk 5 Alcohol < 300 mL/d but > 0
5
Red meat ≤ 1/wk 5
Fish > 6/wk 5
Poultry ≤ 3/wk 5
Morris MC, et al. Alzheimers Dement 2015;11(9):1007-1014.
4/3/2018
18
MIND (max total score 15)Components Max score Components Max score
Whole grains ≥ 3/d 1 Nuts ≥ 5/wk 1
Green leafy ≥ 6/wk 1 Fast/fried food < 1/wk
1
Other Vegetables ≥ 1/d
1 Olive Oil primary oil 1
Berries ≥ 2/wk 1 Butter, margarine < 1 T/d
1
Red Meats & products < 4/wk
1 Cheese < 1/wk 1
Fish ≥ 1/wk 1 Pastries, sweets < 5/wk
1
Poultry ≥ 2/wk 1 Alcohol/wine 1/d 1
Beans ≥ 3/wk 1Morris MC, et al. Alzheimers Dement 2015;11(9):1007-1014.
Diet Scores
Morris MC, et al. Alzheimers Dement 2015;11(9):1007-1014.
Tertile 1 Tertile 2 Tertile 3 P for Linear Trend
DASHScore range 1.0 - 3.5 4.0 - 4.5 5.0 - 8.5HR 1.0 0.98 0.6195% CI Referent 0.66, 1.46 0.38, 0.97 0.07
MediterraneanScore range 18 - 29 30 - 34 35 - 46 HR 1.0 0.81 0.4695% CI Referent 0.54, 1.24 0.27, 0.79 0.006
MINDScore range 2.5 - 6.5 7 - 8 8.5 - 12.5HR 1.0 0.65 0.4795% CI Referent 0.44, 0.98 0.29, 0.76 0.002
CerefolinNAC: L-methylfolate 6 mg, methyl-cobalamin 2 mg, N-acetylcysteine 600 mg
Participants ResultsHHcy+CFLN (N=34) vs NoHHcy+NoCFLN(N=82)2
No B vit supp
AD, VD, mixed dementia
Slower rate of cognitivedeclineRelated to: Hcy reduction from baseline, duration of CFLN, milder baseline severity
HHcy+CFLN (N=30) vs NoHHcy+NoCFLN(N=37)2
No B vit suppHHcy: Hcy ≥ 12 umol/L
AD or cognitive impairment due to cerebrovascular disease
CFLN for 2 or more yrs: Delayed hippocampal & cortical atrophy rateRelated to: greater Hcylowering, longer CFLN duration, milder baseline severity
1Henderson ST, et al. Nutr Metab 2009;6(31).
2Shankle WR, et
al. J Alzheimers Dis 2016;54(3):1073-1084.
4/3/2018
19
Medical FoodsMedical Foods Participants ResultsSouvenaid1,2
Contains DHA 1200 mg & EPA 300 mg, B vitamins 1 mg, uridinemonophosphate 625 mg, choline 400 mg, & phospholipids 106 mg
N = 26Age = 50-65 yrsBehavioral variant of frontotemporal dementia
Treatment vs placebo: Significant reduction of behavioral symptomsIncrease in Theory of Mind skillNo effect on executive functions
N = 259Age = 50+ yrs
Drug-naïve pts with mild AD: Improved memory performance
1Pardini M, et al. Neurodegener Dis 2014;15(1):58-62.
2Scheltens P, et al. J Alzheimers Dis 2012;31(1):225-36.
Reversal of cognitive decline
• 10 patients, memory loss: Alzheimer’s disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI)
• Nine of 10: subjective or objective improvement in cognition beginning within 3-6 months; one failure: very late stage AD
• Six patients: – Discontinued working or were struggling with their jobs
at time of presentation– All able to return to work or continue working with
improved performance• Longest patient f/u: 2½ years from initial treatment, with
sustained & marked improvement
Aging 2014; 6: 707-717
Metabolic enhancement for neurodegeneration (MEND) protocol
Goal Approach
Optimize diet: minimize simple CHO, minimize inflammation
Choice of several low glycemic, low inflammatory, low grain diets
Enhance autophagy, ketogenesis
Fast 12 hr each night, including 3 hr prior to bedtime
Reduce stress Yoga or meditation or music, etc
Optimize sleep 8 hr sleep per night, melatonin 0.5 mg po qhs; Tryptophan 500 mg po 3x/wk if awakening. Exclude sleep apnea.
Brain stimulation Posit or related
Aging 2014; 6: 707-717
4/3/2018
20
Metabolic enhancement for neurodegeneration (MEND) protocol
Goal Approach
Homocysteine < 7 Me-B12, MTHF, P5P, TMG if necessary
Serum B12 > 500 Me-B12
CRP < 1.0, A/G > 1.5 Anti-inflammatory diet; curcumin; DHA/EPA; optimize hygiene
Fasting insulin < 7; HgA1C < 5.5
Diet as above
Hormone balance Optimize fT3, fT5, E2, T, progesterone, pregnenolone, cortisol
GI health Repair if needed; prebiotics & probiotics
Aging 2014; 6: 707-717
Metabolic enhancement for neurodegeneration (MEND) protocol
Goal Approach
Reduction of A-beta Curcumin, Ashwagandha
Cognitive enhancement Bacopa monniera, Mg Threonate
25(OH)D3 = 50-100 ng/mL Vitamins D3, K2
Increase NGF H. erinaceus or ALCAR
Provide synaptic structuralcomponents
Citicoline, DHA
Optimize antioxidants Mixed tocopherols & tocotrienols, Se, blueberries, NAC, ascorbate, α-lipoic acid
Aging 2014; 6: 707-717
Metabolic enhancement for neurodegeneration (MEND) protocol
Goal Approach
Optimize Zn:fCu ratio Depends on values obtained
Ensure noctural oxygenation Exclude or treat sleep apnea
Optimize mitochondrial function
CoQ or ubiquinol, α-lipoic acid, PQQ, NAC, ALCAR, Se, Zn, resveratrol, ascorbate, thiamine
Increase focus Pantothenic acid
Exclude heavy metal toxicity Evaluate Hg, Pb, Cd; chelate if indicated
MCT effects Coconut oil or Axona
Aging 2014; 6: 707-717
4/3/2018
21
Metabolic enhancement for neurodegeneration (MEND) protocol• Decrease in:
– hs-CRP– Fasting insulin– HbA1c– Homocysteine
• Increase in:– 25OH vitamin D– MMSE– MoCA– Hippocampal volume
• Improvement in:– Memory– Recall– Processing speed– Executive function
Aging 2016; 8: 1250-1258
ConclusionNutritional Intervention
Result
Folic acid Lowered Hcy and improved cognition
Vitamin E Improvement in cognition
Alpha-lipoic acid Improved cognition in patients with diabetes
Omega 3 Reduced incidence of dementia; improvements in cognition in healthy adults and in very mild dementia
Curcumin Improved cognition in healthy adults
Sage Decreased AChE activity and improvements in cognition in patients with dementia
DASH and MeDidiets
Only high adherence was associated with cognitive improvement
MIND diet Even moderate adherence reduced risk of AD
Thank You!
Speaker Contact Information:
Melody ArmitehUSC School of PharmacyEmail: armiteh@usc.edu
Naomi QuintUSC School of PharmacyEmail: quint@usc.edu
Kelly TranUSC School of PharmacyEmail: kellytra@usc.edu
Cynthia Lieu, Pharm.D., BCNSPUSC School of PharmacyOffice: (323) 442-1472Email: CLLLieu@usc.edu
top related